Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes.
Pharmacogenomics., Mar;12(3):327-39 (2011)
Randomized trial of 2 dosages of prophylactic granulocyte-colony-stimulating factor after induction chemotherapy in pediatric acute myeloid leukemia.
Cancer., Mar;117(6):1313-20 (2011)
Efficacy of high-dose methotrexate, ifosfamide, etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphoma.
Ann. Oncol., Feb;22(2):468-71 (2011)
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.
Lancet Oncol., Jun;11(6):543-52 (2010)
Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia.
Cancer., Jan;116(1):98-105 (2010)
Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial.
Leukemia., Aug;23(8):1410-6 (2009)
Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study.
Leukemia., Jun;23(6):1127-30 (2009)
Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital.
Blood., May;113(21):5083-9 (2009)
Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis.
Cancer., Aug;113(3):522-9 (2008)
Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia.
Cancer., Jul;113(2):376-82 (2008)
Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.
Blood., Jan;111(2):566-73 (2008)
Creating a palliative and end-of-life program in a cure-oriented pediatric setting: the zig-zag method.
J Pediatr Oncol Nurs., 24(5):246-54 (2007 Sep-Oct)
Prognostic significance of myeloperoxidase expression in childhood acute myeloid leukemia.
Pediatr Blood Cancer., Mar;50(3):542-8 (2008)
BK virus-induced tubulointerstitial nephritis in a child with acute lymphoblastic leukemia.
J. Pediatr., Aug;151(2):215-7 (2007)
Nocturnal awakenings, sleep environment interruptions, and fatigue in hospitalized children with cancer.
Oncol Nurs Forum., Mar;34(2):393-402 (2007)
Obesity in survivors of childhood acute lymphoblastic leukemia and lymphoma.
J. Clin. Oncol., Apr;25(10):1183-9 (2007)
Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia.
JAMA., Mar;297(11):1207-15 (2007)
Clinical field testing of an enhanced-activity intervention in hospitalized children with cancer.
J Pain Symptom Manage., Jun;33(6):686-97 (2007)
Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia.
Cancer., Jan;109(1):157-63 (2007)
Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia.
Blood., Dec;108(13):3997-4002 (2006)
Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia.
Blood., Nov;108(10):3302-4 (2006)
Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy.
J. Clin. Oncol., Aug;24(22):3583-9 (2006)
Effect of race on outcome of white and black children with acute myeloid leukemia: the St. Jude experience.
Pediatr Blood Cancer., Jan;48(1):10-5 (2007)
Impact of age on outcome of pediatric acute myeloid leukemia: a report from 2 institutions.
Cancer., Jun;106(11):2495-502 (2006)
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
J. Clin. Oncol., Apr;24(12):1917-23 (2006)
Pharmacokinetics and pharmacodynamics of intravenous epoetin alfa in children with cancer.
Pediatr Blood Cancer., Oct;47(5):572-9 (2006)
Successive clinical trials for childhood acute myeloid leukemia at St Jude Children's Research Hospital, from 1980 to 2000.
Leukemia., Dec;19(12):2125-9 (2005)
Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia.
J. Clin. Oncol., Nov;23(31):7936-41 (2005)
Reinduction of relapsed acute promyelocytic leukemia with ATRA and low dose antimetabolite-based chemotherapy.
Pediatr Blood Cancer., May;48(5):582-5 (2007)
Overt testicular disease at diagnosis of childhood acute lymphoblastic leukemia: lack of therapeutic role of local irradiation.
Leukemia., Aug;19(8):1399-403 (2005)
Typhlitis in childhood cancer.
Cancer., Jul;104(2):380-7 (2005)
Cancer-related deaths in children and adolescents.
J Palliat Med., Feb;8(1):86-95 (2005)
Clinical presentation and treatment outcome of children with Burkitt lymphoma in Lebanon: a single institution's experience.
J. Pediatr. Hematol. Oncol., Nov;26(11):749-53 (2004)
Death during induction therapy and first remission of acute leukemia in childhood: the St. Jude experience.
Cancer., Oct;101(7):1677-84 (2004)
Severe cardiopulmonary complications consistent with systemic inflammatory response syndrome caused by leukemia cell lysis in childhood acute myelomonocytic or monocytic leukemia.
Pediatr Blood Cancer., Jan;44(1):63-9 (2005)
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital.
Blood., Nov;104(9):2690-6 (2004)
Phase II trial of cladribine and cytarabine in relapsed or refractory myeloid malignancies.
Leuk. Res., Apr;28(4):349-52 (2004)
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse.
Leukemia., Mar;18(3):499-504 (2004)
Results of therapy for acute lymphoblastic leukemia in black and white children.
JAMA., Oct;290(15):2001-7 (2003)
Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia.
Br. J. Haematol., Oct;123(2):243-52 (2003)
Epstein-Barr virus in pediatric Hodgkin disease: age and histiotype are more predictive than geographic region.
Med. Pediatr. Oncol., Apr;28(4):248-54 (1997)
A phase II evaluation of thiotepa followed by other multiagent chemotherapy regimens in infants and young children with malignant brain tumors.
Cancer., Jun;75(11):2762-7 (1995)